Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer

Citations Over TimeTop 10% of 2016 papers

Abstract

Clear cell renal cell carcinoma (ccRCC) is characterized by loss of function of the von Hippel-Lindau tumour suppressor (VHL) and unrestrained activation of hypoxia-inducible transcription factors (HIFs). Genetic and epigenetic determinants have an impact on HIF pathways. A recent genome-wide association study on renal cancer susceptibility identified single-nucleotide polymorphisms (SNPs) in an intergenic region located between the oncogenes MYC and PVT1. Here using assays of chromatin conformation, allele-specific chromatin immunoprecipitation and genome editing, we show that HIF binding to this regulatory element is necessary to trans-activate MYC and PVT1 expression specifically in cells of renal tubular origins. Moreover, we demonstrate that the risk-associated polymorphisms increase chromatin accessibility and activity as well as HIF binding to the enhancer. These findings provide further evidence that genetic variation at HIF-binding sites modulates the oncogenic transcriptional output of the VHL-HIF axis and provide a functional explanation for the disease-associated effects of SNPs in ccRCC.

Related Papers

• → Increased enhancer–promoter interactions during developmental enhancer activation in mammals(2024)79 cited
• → Promoter targeting sequence mediates enhancer interference in the Drosophila embryo(2007)20 cited
• → Recruitment of Transcription Complexes to Enhancers and the Role of Enhancer Transcription(2012)9 cited
• → Dissection of thousands of cell type-specific enhancers identifies dinucleotide repeat motifs as general enhancer features(2014)154 cited
• → Increased Enhancer-Promoter Interactions during Developmental Enhancer Activation in Mammals(2022)11 cited